Published Date: 08 Mar 2023
The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).
Read Full News1.
Studies point to redlining as a 'perfect storm' for breast cancer
2.
Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma
3.
Many Americans unaware of links between HPV and cancers, poll reveals
4.
FDA Approves Hemophilia B Second Gene Therapy.
5.
In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.
1.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
2.
Liquid Biopsies and ctDNA: Transforming Cancer Detection, Monitoring, and Clinical Decisions
3.
Navigating the Complexities of Esophageal Cancer Staging
4.
Understanding Dasatinib: A Promising Drug for Cancer Treatment
5.
Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part V
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
4.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
5.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation